NCT02556320 (VIRIDAE) is a NA clinical trial of anti-epileptic drug in Epilepsy, sponsored by University Hospital, Rouen.

Who is sponsoring NCT02556320?

NCT02556320 is sponsored by University Hospital, Rouen.

What drugs are being tested in NCT02556320?

Interventions in NCT02556320: anti-epileptic drug, Blood sampling.

What condition does NCT02556320 study?

NCT02556320 studies Epilepsy, Drug Hypersensitivity Syndrome.

Is NCT02556320 still recruiting?

NCT02556320 is currently completed. Last updated 22 January 2016.

Last reviewed 2016-01-22 · How we verify

NCT02556320: VIRIDAE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs

Completed NA Last updated 22 January 2016

What this trial tests

NA trial testing anti-epileptic drug in Epilepsy in 30 participants. Completed in 1 December 2015.

Timeline

1 May 2013

Primary endpoint
1 August 2015

1 December 2015

Quick facts

Lead sponsor	University Hospital, Rouen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	1 May 2013
Primary completion	1 August 2015
Estimated completion	1 December 2015
Sites	1 location across France

Drugs / interventions tested

anti-epileptic drug — full drug profile →
Blood sampling — full drug profile →

Conditions studied

Epilepsy — all drugs for Epilepsy →
Drug Hypersensitivity Syndrome — all drugs for Drug Hypersensitivity Syndrome →

Sponsor

University Hospital, Rouen

Who can join

18 and older, any sex, with Epilepsy or Drug Hypersensitivity Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of patients with viral reactivation of Epstein-Barr Virus
Time frame: 3 Months
Number of patients with viral reactivation of Epstein-Barr Virus is evaluated in patients initiating an anti-epileptic treatment
Number of patients with viral reactivation of Human Herpes Virus 6
Time frame: 3 Months
Number of patients with viral reactivation of Human Herpes Virus 6 is evaluated in patients initiating an anti-epileptic treatment
Number of patients with viral reactivation of Human Herpes Virus 7
Time frame: 3 Months
Number of patients with viral reactivation of Human Herpes Virus 7 is evaluated in patients initiating an anti-epileptic treatment

Sponsor's own description

A recent study has shown that certain drug allergies were actually related to an immune system against certain viruses. The aim of the study is to evaluate, in patients taking antiepileptic drugs, if this treatment induces proliferation of these viruses and secondarily an immune response that would promote the development of a rash. In particular, will be studied whether these drugs can induce virus reactivation "dormant" in the immune system. This study will not affect the usual follow-up proposed by investigators, with the exception of some additional blood samples.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other University Hospital, Rouen trials

Trials by the same sponsor.

NCT07441564 — Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Jux · NA · not yet recruiting
NCT07535944 — Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors · not yet recruiting
NCT07464184 — Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension · NA · not yet recruiting
NCT07359885 — Prediction of Postoperative Pulmonary Complications in Thoracic Surgery · not yet recruiting
NCT07247500 — Impact of Reventilation After One-Lung Ventilation in Thoracic Surgery (OLVREEXP) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02556320 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Rouen
Last refreshed: 22 January 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02556320.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing